The genomic landscape of response to EGFR blockade in colorectal cancer
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Colorectal cancer is the third most common cancer worldwide, with 1.2 million patients diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted therapies are the monoclonal antibodies cetuximab and panitumumab, which prevent epidermal growth factor receptor (EGFR) activation. Recent studies have identified alterations in KRAS and other genes as likely mechanisms of primary and secondary resistance to anti-EGFR antibody therapy. Despite these efforts, additional mechanisms of resistance to EGFR blockade are thought to be present in colorectal cancer and little is known about determinants of sensitivity to this therapy. To examine the effect of somatic genetic changes in colorectal cancer on response to anti-EGFR antibody therapy, here we perform complete exome sequence and copy number analyses of 129 patient-derived tumour grafts and targeted genomic analyses of 55 patient tumours, all of which were KRAS wild-type. We analysed the response of tumours to anti-EGFR antibody blockade in tumour graft models and in clinical settings and functionally linked therapeutic responses to mutational data. In addition to previously identified genes, we detected mutations in ERBB2, EGFR, FGFR1, PDGFRA, and MAP2K1 as potential mechanisms of primary resistance to this therapy. Novel alterations in the ectodomain of EGFR were identified in patients with acquired resistance to EGFR blockade. Amplifications and sequence changes in the tyrosine kinase receptor adaptor gene IRS2 were identified in tumours with increased sensitivity to anti-EGFR therapy. Therapeutic resistance to EGFR blockade could be overcome in tumour graft models through combinatorial therapies targeting actionable genes. These analyses provide a systematic approach to evaluating response to targeted therapies in human cancer, highlight new mechanisms of responsiveness to anti-EGFR therapies, and delineate new avenues for intervention in managing colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“EGFR somatic sequence changes, including G465R, G465E, S468R and S492R, located at the extracellular domains (ECDs) of the EGFR-mAb interaction interface, confer resistance to cetuximab and panitumumab by preventing mAb binding [10, 67, 68].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, in late-line therapy, only 12–17% of patients have durable responses to anti-EGFR monotherapy [4]”
From Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer (2020) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Gene mutations downstream of the EGFR signalling pathway, including RAS/RAF/MEK and PI3K/AKT/mTOR, significantly contribute to drug resistance [9–11].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [10]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This is supported by our observation, consolidated after monitoring hundreds of mCRC PDXs exposed to cetuximab (10, 25, 27, 29, 30), that complete responses are exceptional events.”
From Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer (2023) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“A growing number of studies suggest that mutations in the extracellular domain (ECD) of the EGFR, such as S492R, G465E, R451C and K467T, prevent binding cetuximab and make CRC resistant to anti-EGFR mAbs [141,142,143,144].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [144]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Needleman, S. B., & Wunsch, C. D. (1970) · Journal of Molecular Biology · doi:10.1016/0022-2836(70)90057-4 · Cited by 11,288 · cited 1×
“Sequence reads were aligned against the human reference genome (version hg18) using ELAND with additional realignment of select regions using the Needleman-Wunsch method 35 .”
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“A mutation in the tumour was identified as a candidate somatic mutation only when (1) distinct paired reads contained the mutation in the tumour, (2) the number of distinct paired reads containing a particular mutation in the tumour was at least 2% of the total distinct read pairs for targeted analyses and 10% of read…”
Self-citationThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Self-citationPDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C.-J., Joseph, N., Singer, S., Griffith, D. J., Haley, A., Town, A., et al. (2003) · Science · doi:10.1126/science.1079666 · Cited by 2,301
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 6×
“Common CRC driver genes were identified at expected frequencies in the tumours analysed (Supplementary Tables 3–5).”
InfluentialSelf-citationThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Coiffier, B., Osmanov, E. A., Hong, X., Scheliga, A. A. D. S., Mayer, J., Offner, F., Rule, S. A., Teixeira, A., Walewski, J. A., Vos, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045 · Cited by 1,631
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Cited by
Items 101–200 of 478
Pharmacoproteomic characterisation of human colon and rectal cancer
Frejno, M., Chiozzi, R. Z., Wilhelm, M., Koch, H., Zheng, R., Klaeger, S., Ruprecht, B., Meng, C., Kramer, K., Jarząb, A., et al. (2017) · Molecular Systems Biology · doi:10.15252/msb.20177701 · Cited by 62
“While activating mutations of K57 in MAP2K1 are known to play a role in the development of resistance towards EGFR-targeted treatments (Bertotti et al, 2015), to our knowledge, MERTK was so far only shown to be up-regulated on the mRNA level in pancreatic cancer cell lines resistant towards the…”
BackgroundResultMartini, G., Ciardiello, D., Vitiello, P. P., Napolitano, S., Cardone, C., Cuomo, A., Troiani, T., Ciardiello, F., & Martinelli, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102023 · Cited by 58
Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments
Tang, Y., Li, D., Duan, J.-Y., Sheng, L., & Wang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i6.926 · Cited by 66
Joosten, S. P. J., Zeilstra, J., van Andel, H., Mijnals, R. C. D., Zaunbrecher, J., Duivenvoorden, A. A. M., van de Wetering, M., Clevers, H. C., Spaargaren, M., & Pals, S. T. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.07.008 · Cited by 60
Ortíz, R., Quiñonero, F., García-Pinel, B., Fuel, M., Mesas, C., Cabeza, L., Melguizo, C., & Prados, J. C. (2021) · Cancers · doi:10.3390/cancers13092058 · Cited by 64
Evolving neoantigen profiles in colorectal cancers with DNA repair defects
Rospo, G., Lorenzato, A., Amirouchene-Angelozzi, N., Magrì, A., Cancelliere, C., Corti, G., Negrino, C., Amodio, V., Montone, M., Bartolini, A., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0654-6 · Cited by 60
Self-citationSever, B., Altıntop, M. D., Özdemır, A., Çiftçi, G. A., Ellakwa, D. E., Tateishi, H., Radwan, M. O., Ibrahim, M. A. A., Otsuka, M., Fujita, M., et al. (2020) · Molecules · doi:10.3390/molecules25215190 · Cited by 55
Huang, L. J., Wen, C., Yang, X., Lou, Q., Wang, X., Che, J., Chen, J., Yang, Z., Wu, X., Huang, M., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0320-8 · Cited by 56
Gharib, E., & Robichaud, G. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179463 · Cited by 65
The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer
Mandel, A., Larsson, P., Sarwar, M., Semenas, J., Khaja, A. S. S., & Persson, J. L. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0035-4 · Cited by 55
“During the past years, several new classes of inhibitors against EGFR have been developed and have shown promising effects in targeting metastasized cancers of the lung, breast, colorectal system, and head and neck (Bertotti et al. 2015; Blaszczak et al. 2017; Chong and Jänne 2013; Munagala et al. 2011).”
BackgroundCOL1A1: A potential therapeutic target for colorectal cancer expressing wild-type or mutant KRAS
Zhang, Z., Fang, C., Wang, Y., Zhang, J., Yu, J., Zhang, Y., Wang, X., & Zhong, J. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4536 · Cited by 53
“Cetuximab is a chimeric IgGl anti-EGFR monoclonal antibody, while panitumumab is a complete human IgG2 anti-EGFR COL1A1: A potential therapeutic target for colorectal cancer expressing wild-type or mutant KRAS monoclonal antibody (9).”
InfluentialGuo, Y., Wu, Z., Shen, S., Guo, R., Wang, J., Wang, W., Zhao, K., Kuang, M., & Shuai, X. (2018) · Nature Communications · doi:10.1038/s41467-018-05764-7 · Cited by 54
RetractedReceptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer
Jiang, W., & Ji, M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.03.006 · Cited by 62
Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer
Rizzo, G., Bertotti, A., Leto, S. M., & Vetrano, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01970-2 · Cited by 51
Self-citationLiquid Biopsy in Tumor Genetic Diagnosis
Jung, A., & Kirchner, T. (2018) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2018.0169 · Cited by 55
Iavarone, C., Zervantonakis, I. K., Selfors, L. M., Palakurthi, S., Liu, J. F., Drapkin, R., Matulonis, U. A., Hallberg, D., Velculescu, V. E., Leverson, J. D., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0413 · Cited by 52
“Genomic sequencing of the PDX models, including sample library construction, targeted capture, nextgeneration sequencing, and bioinformatics analyses were performed as previously described (27, 30, 31).”
MethodSelf-citationCombined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer
Cohen, A. S., Geng, L., Zhao, P., Fu, A., Schulte, M. L., Graves-Deal, R., Washington, M. K., Berlin, J., Coffey, R. J., & Manning, H. C. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100828 · Cited by 49
Preclinical models for precision oncology
Ibarrola‐Villava, M., Cervantes, A. M. R., & Bardelli, A. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.004 · Cited by 58
Salem, M. E., Battaglin, F., Goldberg, R. M., Puccini, A., Shields, A. F., Arguello, D., Korn, W. M., Marshall, J. L., Grothey, A. F., & Lenz, H. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0552 · Cited by 52
“In addition, growing evidence is accumulating on the negative predictive impact of PIK3CA mutations, loss of PTEN function, and activating mutations of the MAPKs or PI3 K/AKT axis on anti-epidermal growth factor (EGFR) drugs activity [29, 30], which may partially explain the observed absence of benefit from anti-EGFRs…”
BackgroundChoosing wisely – Preclinical test models in the era of precision medicine
Klinghammer, K. F., Walther, W., & Hoffmann, J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.02.009 · Cited by 52
Comparative molecular profiling of HPV‐induced squamous cell carcinomas
Koncar, R. F., Feldman, R. A., Bahassi, E. M., & Sadraei, N. H. (2017) · Cancer Medicine · doi:10.1002/cam4.1108 · Cited by 50
Biomarkers and Immunotherapeutic Targets in Glioblastoma
Hung, A. L., Garzón-Muvdi, T., & Lim, M. K. (2017) · World Neurosurgery · doi:10.1016/j.wneu.2017.03.011 · Cited by 53
Schwarz, L. J., Hutchinson, K. E., Rexer, B. N., Estrada, M. V., Ericsson, P. I. G., Sanders, M. E., Dugger, T. C., Formisano, L., Zotano, Á. G., Red-Brewer, M., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx065 · Cited by 50
Self-citationJoosten, S. P. J., Spaargaren, M., Clevers, H. C., & Pals, S. T. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188437 · Cited by 53
USP19 exacerbates lipogenesis and colorectal carcinogenesis by stabilizing ME1
Zhu, Y., Gu, L., Lin, X., Zhou, X., Lu, B., Liu, C., Lei, C., Zhou, F., Zhao, Q., Prochownik, E. V., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110174 · Cited by 48
Inoue, A., Deem, A. K., Kopetz, S., Heffernan, T. P., Draetta, G. F., & Carugo, A. (2019) · Cancers · doi:10.3390/cancers11091321 · Cited by 45
“Comprehensive genomic analyses of tumors from both PDX models and patients whose tumor responded to anti-EGFR antibody blockade detected mutations in ERBB2, EGFR, FGFR1, PDGFRA, and MAP2K1 as potential mechanisms of primary resistance to this therapy [15].”
BackgroundKhotskaya, Y. B., Mills, G. B., & Shaw, K. R. M. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-102115-021556 · Cited by 46
Zhang, F., Lu, Y., Chen, Q., Zou, H., Zhang, J., Hu, Y., Li, X., Zhang, W., Zhang, W., Lin, C., et al. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.04.020 · Cited by 47
Chamberlain, C. E., German, M. S., Yang, K. Y., Wang, J., VanBrocklin, H. F., Regan, M., Shokat, K. M., Ducker, G. S., Kim, G., Hann, B. C., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1204 · Cited by 49
“The variability in response may be due to the heterogeneous nature of the PDX-PNET model (23-25) or experimental variation.”
Genetic Alterations of Metastatic Colorectal Cancer
Testa, U., Castelli, G., & Pelosi, E. (2020) · Biomedicines · doi:10.3390/biomedicines8100414 · Cited by 44
“The results of this analysis showed the existence of positive associations between EGFR and KRAS, EGFR and SMAD4, BRAF and PTEN, and NRAS and TP53 mutations, whose biological and clinical significance is at the moment unknown [25].”
BackgroundInfluentialSun, H. J., Zhang, H., Zhang, A., Zhou, X., Wang, X., Han, Y., Yan, G., Liu, L., & Wang, X. (2018) · RSC Advances · doi:10.1039/c8ra04886j · Cited by 45
A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology
Corti, G., Bartolini, A., Crisafulli, G., Novara, L., Rospo, G., Montone, M., Negrino, C., Mussolin, B., Buscarino, M., Isella, C., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.02.008 · Cited by 47
Self-citationXu, J., Wang, P., Yang, H. J., Zhou, J., Li, Y., Li, X., Xue, W., Yu, C., Tian, Y., & Zhu, F. (2016) · BioMed Research International · doi:10.1155/2016/2509385 · Cited by 47
“In themeantime, EGFRwas reported to play critical roles in and acted as primary target for nonsmall cell lung cancer [47], breast cancer [48], and colorectal cancer [49, 50].”
Johnson, R. M., Qu, X., Lin, C.-F., Huw, L.-Y., Venkatanarayan, A., Sokol, E., Ou, F.-S., Ihuegbu, N., Zill, O. A., Kabbarah, O., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33172-5 · Cited by 42
Jeong, J. H., Kim, J., Hong, Y. S., Kim, D., Kim, J. E., Kim, S. Y., Kim, K., Yoon, Y., Kim, D., Chun, S., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.01.005 · Cited by 49
“In reviewing the literature, the incidence of HER2 amplification in unselected mCRC was reported to be about 1% to 6%.(18,23,28) In particular, in KRAS exon 2 wild-type mCRC, HER2 amplification was detected in 4% to 5% of cases.”
BackgroundRachiglio, A. M., Lambiase, M., Fenizia, F., Roma, C., Cardone, C., Iannaccone, A., De Luca, A., Carotenuto, M., Frezzetti, D., Martinelli, E., et al. (2019) · Cancers · doi:10.3390/cancers11060859 · Cited by 43
“Lys57Glu) in the MEK1 negative regulatory domain and it has been associated with a gain of function of the protein [14,15].”
BackgroundChen, Y., Zhang, R., Wang, L., Correa, A. M., Pataer, A., Xu, Y., Zhang, X., Ren, C., Wu, S., Meng, Q. H., et al. (2019) · Cancer · doi:10.1002/cncr.32366 · Cited by 42
Erve, I. V. ’., Medina, J. E., Leal, A., Papp, E., Phallen, J. A., Adleff, V., Chiao, E. J., Arun, A. S., Bolhuis, K., Simmons, J. K., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2538 · Cited by 49
“These patients are suited to evaluate treatment response monitoring as not all patients respond (21), while those who initially respond are prone to develop acquired resistance over time (22 – 24).”
Self-citationZhu, X., Tian, X., Ji, L., Zhang, X., Cao, Y., Shen, C., Hu, Y., Wong, J. W. H., Fang, J.-Y., Hong, J., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00142-x · Cited by 41
Yao, Y., Wang, Y., Chen, L., Tian, Z., Yang, G., Wang, R., Wang, C., Wu, Q., Wu, Y., Gao, J., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00908-0 · Cited by 47
“PCT studies of CRCs have validated KRAS mutation as an informative biomarker for cetuximab resistance;21,47 these findings have actually supported revision of the NCCN guidelines for use of cetuximab for CRCs.48 In addition, several PCT studies revealed that mutations in genes including NRAS, BRAF, FGFR1, and PIK3CA (…”
BackgroundInfluentialRichiardone, E., Roumi, R. A., Lardinois, F., Giolito, M. V., Ambroise, J., Boidot, R., Drotleff, B., Ghesquière, B., Bellahcène, A., Bardelli, A., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217091 · Cited by 43
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab
Iida, M., Bahrar, H., Brand, T. M., Pearson, H. E., Coan, J. P., Orbuch, R. A., Flanigan, B. G., Swick, A. D., Prabakaran, P. J., Lantto, J., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0012 · Cited by 43
“Recently, mutations in the genes encoding other RTKs, such as FGFR1or PDGFRA,were found inCRCPDXmodelswith intrinsic resistance to cetuximab (47).”
BackgroundSelf-citationRankin, A., Klempner, S. J., Erlich, R., Sun, J. X., Grothey, A., Fakih, M., George, T. J., Lee, J., Ross, J. S., Stephens, P. J., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0148 · Cited by 40
Martini, G., Belli, V., Napolitano, S., Ciaramella, V., Ciardiello, D., Belli, A., Izzo, F., Avallone, A., Selvaggi, F., Tasselli, F. M., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101198 · Cited by 45
“The incorporation of complex genomic platforms and circulating tumor DNA (ctDNA) determinations has permitted a more comprehensive biomarker identification and molecular follow-up, which in turn has supported the progressive incorporation of targeted drugs to metastatic colorectal cancer (mCRC) patient treatment pathw…”
BackgroundAnti-EGFR Antibodies in the Management of Advanced Colorectal Cancer
Kasi, P. M., Afable, M. G., Herting, C. J., Lukanowski, M., & Jin, Z. (2023) · The Oncologist · doi:10.1093/oncolo/oyad262 · Cited by 47
“41 A complete exome sequence and copy number analysis of KRAS wild-type tumors showed that therapeutic resistance to anti-EGFR therapies can be overcome through combinatorial therapies targeting actionable genes.”
BackgroundMethodBeekhof, R., Bertotti, A., Böttger, F., Vurchio, V., Cottino, F., Zanella, E. R., Migliardi, G., Viviani, M., Grassi, E., Lupo, B., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abm3687 · Cited by 39
“In this study, we combined mass spectrometry–based proteomics with global (TiO2) and pTyr-based phosphoproteomics to analyze a unique panel of 30 genomically characterized mCRCPDX tumors annotated for response to cetuximab as seen in the clinic and confirmed in the mouse setting (10).”
BackgroundMethodInfluentialSelf-citationPerivascular PDGFR-β is an independent marker for prognosis in renal cell carcinoma
Frödin, M., Mezheyeuski, A., Corvigno, S., Harmenberg, U., Sandström, P., Egevad, L., Johansson, M., & Östman, A. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.407 · Cited by 41
“Primary resistance to targeted therapy in other cancers are often linked to mutational events in genes coding for the target receptor (Bertotti et al, 2015).”
BackgroundCYpHER: catalytic extracellular targeted protein degradation with high potency and durable effect
Crook, Z. R., Sevilla, G. P., Young, P., Girard, E. J., Phi, T.-D., Howard, M. L., Price, J., Olson, J. M., & Nairn, N. W. (2024) · Nature Communications · doi:10.1038/s41467-024-52975-2 · Cited by 40
Clifton, K., Rich, T. A., Parseghian, C., Raymond, V. M., Dasari, A., Pereira, A. A. L., Willis, J., Loree, J. M., Bauer, T. M., Chae, Y. K., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00141 · Cited by 37
“© 2019 by American Society of Clinical Oncology Licensed under the Creative Commons Attribution 4.0 License INTRODUCTION Fusions resulting in activation of proto-oncogenes lead to pathologic proliferation in a variety of malignancies and can serve as potential therapeutic targets.1,2 Although selective kinase inhibito…”
BackgroundInfluentialNovoplansky, O., Fury, M. G., Prasad, M., Yegodayev, K. M., Zorea, J., Cohen, L., Pelossof, R., Cohen, L., Katabi, N., Cecchi, F., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32170 · Cited by 41
Belli, V., Matrone, N., Napolitano, S., Migliardi, G., Cottino, F., Bertotti, A., Trusolino, L., Martinelli, E., Morgillo, F., Ciardiello, D., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1230-z · Cited by 37
Self-citationMaitland, M. L., Wilkerson, J., Karovic, S., Zhao, B., Flynn, J. R., Zhou, M., Hilden, P. D., Ahmed, F. S., Dercle, L., Moskowitz, C. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1493 · Cited by 36
“mutations in other genes conferring resistance to EGFR inhibition have been described (45).”
BackgroundBiomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
Ciardiello, D., Martini, G., Famiglietti, V., Napolitano, S., Falco, V. D., Troiani, T., Latiano, T. P., Ros, J., Élez, E., Vitiello, P. P., et al. (2021) · Cancers · doi:10.3390/cancers13081941 · Cited by 38
“In the last years, an increasing number of studies investigated the possible role of anti-EGFR retreatment in the continuum of care of patients with RAS WT mCRC [23].”
BackgroundAtreya, C. E., Yaeger, R., & Chu, E. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175679 · Cited by 35
Hsieh, M., Wu, C., Chen, C.-W. D., Shi, C., Huang, W., & Kuan, F. (2018) · Scientific Reports · doi:10.1038/s41598-018-19835-8 · Cited by 38
Battaglin, F., Puccini, A., Djaballah, S. A., & Lenz, H. (2019) · Cancer Management and Research · doi:10.2147/cmar.s186042 · Cited by 37
“These include HER2 amplification, PIK3CA mutations (exon 9 and 20), MET amplification, FGFR1 and PDGFRA mutations and loss of PTEN function.(65) HER2 amplification, in particular, has recently gained attention as a promising druggable target in mCRC.”
BackgroundXu, Y., Zhao, J., Ni, X., Wang, W., Hu, W., & Wu, C. (2021) · Epigenomics · doi:10.2217/epi-2021-0130 · Cited by 38
MLH1 Deficiency Induces Cetuximab Resistance in Colon Cancer via Her‐2/PI3K/AKT Signaling
Han, Y., Peng, Y., Fu, Y., Cai, C., Guo, C., Liu, S., Li, Y., Chen, Y., Shen, E., Long, K., et al. (2020) · Advanced Science · doi:10.1002/advs.202000112 · Cited by 34
Linden, C. V., & Corbet, C. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.016 · Cited by 34
Genome‐wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy
Sahu, A. D., Lee, J. S., Wang, Z., Zhang, G., Iglesias‐Bartolomé, R., Tian, T., Wei, Z., Miao, B., Nair, N. U., Ponomarova, O., et al. (2019) · Molecular Systems Biology · doi:10.15252/msb.20188323 · Cited by 42
“…characterized tumor-specific molecular signatures of resistance to targeted therapies through DNA and RNA sequencing (Jones et al , 2012; MacArthur et al , 2014; Bertotti et al , 2015; Fong et al , 2015; Miyamoto et al , 2015; Rathert et al , 2015; Wilson et al , 2015; Raphael et al , 2017).”
BackgroundComprehensive Review of Biomarkers for the Treatment of Locally Advanced Colon Cancer
Chuang, J., Tsai, H., Chen, P.-J., Chang, T., Su, W., Yeh, Y., Huang, C., & Wang, J. (2022) · Cells · doi:10.3390/cells11233744 · Cited by 37
Abe, Y., Nagano, M., Kuga, T., Tada, A., Isoyama, J., Adachi, J., & Tomonaga, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-10478-9 · Cited by 34
Ai, H., Tong, Z., Deng, Z., Shi, Q., Tao, S., Sun, G., Liang, J., Sun, M., Wu, X., Zheng, Q., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01750-x · Cited by 38
“Moreover, missense mutations, resulting in R55C, R56H, R57Q, S59L, S60L, W61R and T68I point mutants 63–68 in the RNF168 basic helix of RNF168, and the R63_Y64del mutation 69 have been identified in various cancers (Fig.”
Wang, D., & Bao, B. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s228123 · Cited by 34
Tashiro, T., Okuyama, H., Endo, H., Kawada, K., Ashida, Y., Ohue, M., Sakai, Y., & Inoue, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174151 · Cited by 33
Jing, C., Ma, R., Cao, H., Wang, Z., Liu, S., Chen, D., Wu, Y., Zhang, J., & Wu, J. (2019) · Cancer Medicine · doi:10.1002/cam4.2004 · Cited by 31
Rhein sensitizes human colorectal cancer cells to EGFR inhibitors by inhibiting STAT3 pathway
Zhuang, Y., Bai, Y., Hu, Y., Guo, Y., Xu, L., Hu, W., Yang, L., Zhao, C., Li, X., & Zhao, H. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s206833 · Cited by 32
“In patients with CRC, secondary drug resistance may occur after 10–16 months of treatment, even when early treatment is effective.(6,7) Development of drug resistance has become the bottleneck of EGFRTKIs therapy, which increases the difficulty of clinical treatment of CRC.”
BackgroundTumor Microenvironment in Metastatic Colorectal Cancer: The Arbitrator in Patients’ Outcome
Galindo-Pumariño, C., Collado, M., Herrera, M., & Peña, C. (2021) · Cancers · doi:10.3390/cancers13051130 · Cited by 31
“Claudin-2 Predictive value in chemotherapy-based treated patients [46] Mutation in FGFR1/PDGFRα Primary resistance mechanism to EGFR blocking antibodies [47] CMS4 mesenchymal tumors Resistance to anti-EGFR agents [48,49] FGFR2 amplification Predictive marker of regorafenib sensitivity [50] Interactome signature Associ…”
BackgroundEGFRAmplification in Metastatic Colorectal Cancer
Randon, G., Yaeger, R. D., Hechtman, J. F., Manca, P., Fucà, G., Walch, H. S., Lee, J., Élez, E., Seligmann, J. F., Mussolin, B., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab069 · Cited by 35
Wei, S., Hu, W., Feng, J., & Geng, Y. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00960-x · Cited by 32
Emdal, K. B., Dittmann, A., Reddy, R. J., Lescarbeau, R. S., Moores, S. L., Laquerre, S. G., & White, F. M. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0413 · Cited by 36
A novel immunodeficient rat model supports human lung cancer xenografts
He, D., Zhang, J., Wu, W., Yi, N., He, W., Lü, P., Li, B., Yang, N., Wang, D., Xue, Z., et al. (2018) · The FASEB Journal · doi:10.1096/fj.201800102rr · Cited by 38
Stein-O’Brien, G., Kagohara, L. T., Li, S., Thakar, M., Ranaweera, R. S., Ozawa, H., Cheng, H., Considine, M., Schmitz, S., Favorov, A. V., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0545-2 · Cited by 35
Albadari, N. G., Xie, Y., & Li, W. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1340401 · Cited by 38
Li, Y., Wang, B., Yang, W., Ma, F., Zou, J., Li, K., Tan, S., Feng, J., Wang, Y., Qin, Z., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44911-1 · Cited by 38
“…domain of EGFR that directly confer resistance to antibody blockade 69 , (ii) downstream pathways activated by EGFR, such as RAS-RAF-MAPK-ERK, PI3K-PTEN-AKT, and JAK/STAT pathways mainly through mutations of KRAS , NRAS , BRAF , and MAP2K1 70 – 72 ,andampli fi cationsof MET and ERBB2 73,74 .”
Qu, X., Hamidi, H., Johnson, R. M., Sokol, E. S., Lin, E., Eng, C., Kim, T.-W., Bendell, J. C., Sivakumar, S., Kaplan, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59588-3 · Cited by 37
“Although the mechanisms of acquired resistance to anti-EGFR therapy have been extensively investigated 11,13 – 18 the size and the completeness of this dataset, coupled with the prior treatment information, particularly the inclusion of both anti-EGFR and anti-VEGF treatment cohorts, differentiate…”
InfluentialBattaglin, F., Dadduzio, V., Bergamo, F., Manai, C., Schirripa, M., Lonardi, S., Zagonel, V., & Loupakis, F. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1356815 · Cited by 74
“Several mechanisms of primary resistance to anti-EGFRs have been identified in RAS WT mCRC, based on preclinical data and retrospective evaluations, including HER2 amplification, MET amplification, PIK3CA mutations (exon 9 and 20), low EGFR copy number, FGFR1 and PDGFRA mutations, and loss of PTEN function [61].”
BackgroundErve, I. V. ’., Greuter, M. J. E., Bolhuis, K., Vessies, D. C. L., Leal, A., Vink, G. R., van den Broek, D. A., Velculescu, V. E., Punt, C. J. A., Meijer, G. A., et al. (2020) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2020.09.002 · Cited by 33
Self-citationTargeting Erbin in B cells for therapy of lung metastasis of colorectal cancer
Shen, T., Liu, J., Wang, C.-Y., Rixiati, Y., Shi, L., Cai, L.-D., Zhao, Y., & Li, J. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00501-x · Cited by 31
Leto, S. M., Ferri, M., Sassi, F., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2550 · Cited by 30
“…therapies aimed to increase the depth of response to EGFR inhibition, we evaluated the population-level distribution of tumor response to single-agent cetuximab in a collection of 314mCRC PDXs, established from as many patients, part of which had been used in previous studies(10,25,27,29,30).”
Self-citationGeng, Y., Zheng, X., Zhang, D., Wei, S., Feng, J., Wang, W., Zhang, L., Wu, C., & Hu, W. (2024) · Biology Direct · doi:10.1186/s13062-024-00478-x · Cited by 32
“…may involve abnormal expression or activation of multiple molecules and signaling pathways, including genetic alterations such as mutations in BRAF and PIK3CA, amplification of human epidermal growth factor receptor-2 (HER-2) and MET, PTEN deletion, as well as genome hypermethylation [4, 9, 10].”
BackgroundQuantification of nucleic acid quality in postmortem tissues from a cancer research autopsy program
Fan, J., Khanin, R., Sakamoto, H., Zhong, Y., Michael, C., Pena, D., Javier, B. M., Wood, L. D., & Iacobuzio–Donahue, C. A. (2016) · Oncotarget · doi:10.18632/oncotarget.11836 · Cited by 34
“Sequencing of the human genome has led to a revolution in understanding of cancer etiology by revealing the genetic alterations characteristic of human tumors [5–7], the genetic features that underlie subtypes within a primary tumor type [8–11], or the mechanisms of therapeutic resistance [12–14].”
BackgroundEndonuclease IV-Regulated DNAzyme Motor for Universal Single-nucleotide Variation Discrimination
Zhang, Z., Hu, Y., Yuan, W., Hu, M., Deng, Y., Xiao, X., & Wu, T. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c02230 · Cited by 28
The pharmacogenomics of drug resistance to protein kinase inhibitors
Gillis, N., & McLeod, H. L. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.06.008 · Cited by 33
“…potential markers of intrinsic resistance have since been identified in models of KRAS wildtype patient xenografts, including ERBB2 (HER2), FGFR1, PDGFRA, and MAP2K1 (MEK); secondary mutations in EGFR at the site of cetuximab binding were identified in acquired resistance (Bertotti et al., 2015).”
BackgroundDu, W.-Y., Lu, Z., Ye, W., Fu, X., Zhou, Y., Kuang, C.-M., Wu, J.-X., Pan, Z.-Z., Chen, S., Liu, R., et al. (2017) · 癌症:英文版 · doi:10.1186/s40880-017-0180-0 · Cited by 29
Luraghi, P., Bigatto, V., Cipriano, É., Reato, G., Orzan, F., Sassi, F. P., Bacco, F. D., Isella, C., Bellomo, S. E., Médico, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2151 · Cited by 29
“As observed in xenopatients (8,11), cetuximab-resistant xenospheres mostly harbored KRAS mutations, while most of cetuximab-sensitive xenospheres were quadruple WT (Fig.”
BackgroundMethodInfluentialSelf-citationJacobs, S. A., Lee, J. J., George, T. J., Wade, J. L., Stella, P. J., Wang, D., Sama, A. R., Piette, F., Pogue-Geile, K. L., Kim, R. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1831 · Cited by 27
“in PDX models identified mutations in ERBB2, EGFR, FGFR1, PDGFRA, andMAP2K1 as potential resistance mechanisms (9).”
BackgroundShimada, Y., Kameyama, H., Nagahashi, M., Ichikawa, H., Muneoka, Y., Yagi, R., Tajima, Y., Okamura, T., Nakano, M., Sakata, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20510 · Cited by 30
“We defined patients who had no alterations in all 12 genes as “all wild-type”; theoretically, these patients should respond to anti-EGFR therapy [22, 23].”
BackgroundShimada, Y., Tajima, Y., Nagahashi, M., Ichikawa, H., Oyanagi, H., Okuda, S., Takabe, K., & Wakai, T. (2018) · Journal of Surgical Research · doi:10.1016/j.jss.2018.06.020 · Cited by 31
The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review
Vaghi, C., Mauri, G., Agostara, A. G., Patelli, G., Pizzutilo, E. G., Nakamura, Y., Yoshino, T., Siena, S., & Bianchi, A. S. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102488 · Cited by 30
Self-citationParikh, A. R., Atreya, C. E., Korn, W. M., & Venook, A. P. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0002 · Cited by 28
Pohl, M., & Schmiegel, W. (2016) · Digestive Diseases · doi:10.1159/000445267 · Cited by 26
Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment
Bignucolo, A., Mattia, E. D., Cecchin, E., Roncato, R., & Toffoli, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071522 · Cited by 29
“, BRAF, MEK, PI3K, and AKT), that lead to an auto-activation of these crucial regulatory proteins [41,43,45].”
BackgroundThe GH-EXIN neural network for hierarchical clustering
Cirrincione, G., Ciravegna, G., Barbiero, P., Randazzo, V., & Pasero, E. G. A. (2019) · Neural Networks · doi:10.1016/j.neunet.2019.07.018 · Cited by 33
Rossini, D., Germani, M. M., Pagani, F., Pellino, A., Dell’Aquila, E., Bensi, M., Liscia, N., Moretto, R., Boccaccino, A., Prisciandaro, M., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.03.009 · Cited by 30
Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment
Dienstmann, R., & Tabernero, J. M. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000191 · Cited by 36
“Therapeutic resistance could be overcome with a matched targeted approach, combining anti-EGFR agents and inhibitors of these receptors/kinases in preclinical experiments.(46) In an illustrative case, MEK1 K57T emerged upon treatment with cetuximab, and the patient responded to panitumumab plus MEK inhibitor trametini…”
BackgroundNovel biotechnology approaches in colorectal cancer diagnosis and therapy
Kavousipour, S., Khademi, F., Zamani, M., Vakili, B., & Mokarram, P. (2017) · Biotechnology Letters · doi:10.1007/s10529-017-2303-8 · Cited by 26
“…and KRAS exons 3-4 and also mutations in other signaling pathways such as C-METandEGFR1 are effective factors in resistance to anti EGFR therapies (Bertotti et al. 2015; Broadbridge et al. 2012; Di Fiore et al. 2007; Karapetis et al. 2008; Linardou et al. 2008; Mao et al. 2012; Van Cutsem et al.…”
BackgroundHNF1A regulates colorectal cancer progression and drug resistance as a downstream of POU5F1
Fujino, S., Miyoshi, N., Ito, A., Yasui, M., Matsuda, C., Ohue, M., Uemura, M., Mizushima, T., Doki, Y., & Eguchi, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-89126-2 · Cited by 29
Metastatic colorectal cancer and type 2 diabetes: prognostic and genetic interactions
Ottaiano, A., Circelli, L., Santorsola, M., Savarese, G., Fontanella, D., Gigantino, V., Mauro, A. D., Capuozzo, M., Zappavigna, S., Lombardi, A., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13122 · Cited by 25
Yuan, H.-H., Zhang, X., Wei, X.-L., Zhang, W., Du, X., Huang, P., Chen, H., Bai, L., Zhang, H., & Han, Y. (2021) · Journal of Cancer · doi:10.7150/jca.65687 · Cited by 26
“the integration of cetuximab and standard chemotherapy is a common therapeutic strategy that can improve the response rates and lower the risk of progression to mCRC [2].”
Background
Metadata
- Authors
- Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., Niknafs, N., Nesselbush, M., Lytle, K., Sassi, F., Cottino, F., Migliardi, G., Zanella, E. R., Ribero, D., Russolillo, N., Mellano, A., Muratore, A., Paraluppi, G., Salizzoni, M., Marsoni, S., Kragh, M., Lantto, J., Cassingena, A., Li, Q. K., Karchin, R., Scharpf, R., Sartore-Bianchi, A., Siena, S., Diaz, L. A., Trusolino, L., & Velculescu, V. E.
- Affiliations
- Istituto Nazionale Biostrutture e Biosistemi (IT)
- Johns Hopkins University (US)
- Candiolo Cancer Institute (IT)
- Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
- Symphogen (Denmark) (DK)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- University of Milan (IT)
- Corresponding author
- Bertotti, Andrea
- Trusolino, Livio
- Velculescu, Victor E.
- ORCID
- Bertotti, Andrea
- Papp, Eniko
- Jones, Siân
- Adleff, Vilmos
- Anagnostou, Valsamo
- Lupo, Barbara
- Sausen, Mark
- Phallen, Jillian
- Hruban, Carolyn A.
- Tokheim, Collin
- Niknafs, Noushin
- Nesselbush, Monica
- Sassi, Francesco
- Cottino, Francesca
- Migliardi, Giorgia
- Zanella, Eugenia R.
- Ribero, Dario
- Russolillo, Nadia
- Mellano, Alfredo
- Muratore, Andrea
- Salizzoni, Mauro
- Marsoni, Silvia
- Kragh, Michael
- Lantto, Johan
- Cassingena, Andrea
- Li, Qing Kay
- Karchin, Rachel
- Scharpf, Robert
- Siena, Salvatore
- Diaz, Luis A.
- Trusolino, Livio
- Velculescu, Victor E.
- Venue
- Nature
- Published
- 2015-09-30
- Volume
- 526
- Issue
- 7572
- Pages
- 263-267
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4878148
- OpenAlex
- W2102354469
- Cited by
- 479
- References
- 41
- Citations by year
- 2026: 16 · 2025: 28 · 2024: 37 · 2023: 35 · 2022: 47 · 2021: 50 · 2020: 47 · 2019: 59 · 2018: 56 · 2017: 57 · 2016: 43 · 2015: 3
- FWCI
- 23.15
- Type
- journal article
- Language
- en
- Update notices
- correction (2026-02-16)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (5r01ca121113-15)
- National Cancer Institute (R01-CA121113, CA-121113, P30CA006973)
- National Institute of General Medical Sciences (T32GM007057)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- EGFR inhibition, anti-EGFR antibody therapy, cetuximab, panitumumab, treatment resistance, primary resistance, somatic mutations, ERBB2, FGFR1, PDGFRA, MEK1, KRAS wild-type
- MeSH terms
- Cetuximab, Panitumumab, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Mutation, Colorectal Neoplasms, Genome, Human, Proto-Oncogene Proteins p21(ras), Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, Receptor, Platelet-Derived Growth Factor alpha, Xenograft Model Antitumor Assays, Genomics, MAP Kinase Kinase 1, Mice, Receptor, Fibroblast Growth Factor, Type 1, Insulin Receptor Substrate Proteins, DNA Copy Number Variations, Molecular Targeted Therapy, Exome, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.